newsfilter
← Latest News
GlobeNewswire·

Albireo Reports Q2 2022 Financial Results and Business Update

Bylvay®(odevixibat) Q2 2022 net product revenue $5.9 million, June YTD 2022 $10.5 million Agreed Bylvay reimbursement contract in Italy and Belgium with launches planned for the fall Global Phase 3 ASSERT study in Alagille syndrome on track for topli